Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial
- 18 February 2014
- journal article
- clinical trial
- Published by Elsevier
- Vol. 99 (1) , 50-57
- https://doi.org/10.1016/j.ygyno.2005.05.023
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancerGynecologic Oncology, 2004
- Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma?Journal of Clinical Oncology, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancerThrombosis and Haemostasis, 2004
- Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2003
- Phase II Study of Oxaliplatin in Platinum-Resistant and Refractory Ovarian Cancer: A Gynecologic Group StudyJournal of Clinical Oncology, 2003
- Soluble Urokinase Plasminogen Activator Receptor in Preoperatively Obtained Plasma from Patients with Gynecological Cancer or Benign Gynecological DiseasesGynecologic Oncology, 2001
- Differential mRNA Expression of Urokinase-Type Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor Type-2 in Normal Human Endometria and Endometrial CarcinomasGynecologic Oncology, 2000
- A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivoThe FASEB Journal, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000